Vrisha Madhuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vrisha Madhuri has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
Vivek Dutt
Pediatric Orthopedics Unit, Christian Medical College, Vellore, Tamil Nadu, India
12 shared publicationsAgnes Selina
Department of Paediatric Orthopaedics, Christian Medical College, Vellore, India
9 shared publicationsKarthikeyan Rajagopal
Center for Stem Cell Research, Christian Medical College, Bagayam, Vellore, India
9 shared publicationsSowmya Ramesh
Center for Stem Cell Research, Christian Medical College, Bagayam, Vellore, India
8 shared publicationsMadhavi Kandagaddala
Department of Radiology, Christian Medical College, Vellore, India
7 shared publications- Karthikeyan Rajagopal
Department of Paediatric Orthopaedics, Christian Medical College, Vellore, India
6 shared publications
Latest Publications
- 28 May 2026
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 60 (8) , 1-9
Type V Osteogenesis Imperfecta in an Indian Cohort: Phenotypic Variability and Radiological Insights in IFITM5-Related Bone Fragility
- 28 May 2026
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 60 (8) , 1-9
Type V Osteogenesis Imperfecta in an Indian Cohort: Phenotypic Variability and Radiological Insights in IFITM5-Related Bone Fragility
- 28 July 2025
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 59 (10) , 1-6
Assessment of Bone Density in Osteogenesis Imperfecta in Pediatric and Adolescent Age Group: Can the Metacarpal Index Play a Role?
Background and Objective Osteogenesis Imperfecta (OI), an inherited genetic disorder affecting 1 in 20,000 people worldwide, is currently treated with bisphosphonates for moderate and severe forms. Dual-energy X-ray absorptiometry (DXA) is the standard method for assessing the improvement in bone quality in OI but due to the unavailability of DXA in some places, hand radiographs can be used to calculate the second metacarpal index (MCI) to assess the bone quality in many osteoporotic disorders. In this study we evaluated the feasibility of using metacarpal index to assess the bone quality in OI in children. Methods We evaluated the MCI values in 37 children aged 1–18 years at baseline (before intervention), and following pamidronate treatment in 18 children with type III or type IV OI. Results A decrease in MCI was noted with ageing as anticipated in the OI population, and we also observed an increase in MCI among the younger cohort (under 8 years) receiving pamidronate compared to the older cohort (above 8 years). The change in MCI after pamidronate therapy was monitored, and those who were initiated on pamidronate at a younger age showed more improvement in MCI than those who were started at a later age. Conclusions Our study suggests that when DXA measurements are not feasible, MCI can be a potential tool to assess bone quality and evaluate bisphosphonate therapy in the OI population.
- 28 July 2025
- Published by Springer Nature in Indian Journal of Orthopaedics
- Vol. 59 (10) , 1-6
Assessment of Bone Density in Osteogenesis Imperfecta in Pediatric and Adolescent Age Group: Can the Metacarpal Index Play a Role?
Background and Objective Osteogenesis Imperfecta (OI), an inherited genetic disorder affecting 1 in 20,000 people worldwide, is currently treated with bisphosphonates for moderate and severe forms. Dual-energy X-ray absorptiometry (DXA) is the standard method for assessing the improvement in bone quality in OI but due to the unavailability of DXA in some places, hand radiographs can be used to calculate the second metacarpal index (MCI) to assess the bone quality in many osteoporotic disorders. In this study we evaluated the feasibility of using metacarpal index to assess the bone quality in OI in children. Methods We evaluated the MCI values in 37 children aged 1–18 years at baseline (before intervention), and following pamidronate treatment in 18 children with type III or type IV OI. Results A decrease in MCI was noted with ageing as anticipated in the OI population, and we also observed an increase in MCI among the younger cohort (under 8 years) receiving pamidronate compared to the older cohort (above 8 years). The change in MCI after pamidronate therapy was monitored, and those who were initiated on pamidronate at a younger age showed more improvement in MCI than those who were started at a later age. Conclusions Our study suggests that when DXA measurements are not feasible, MCI can be a potential tool to assess bone quality and evaluate bisphosphonate therapy in the OI population.
- 1 July 2025
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 15 (3)
Atypical Fibrodysplasia Ossificans Progressiva with G328E Variant and Digit Reduction Abnormalities
Case: Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant musculoskeletal disorder with progressive heterotopic ossification within soft connective tissues causing ankyloses and unique skeletal malformations of the big toes, which represent a birth hallmark for the disease. The classic variant is c.617G>A (p.Arg206His). We report 2 atypical FOP cases showing severe digit reduction, associated with a c.983G>A (p.Gly328Glu) variant in exon 8 of the ACVR1 gene. Conclusion: FOP should be ruled out in patients presenting with restricted movements of joints and spine and reduction of digits by clinical examination and molecular genetic analysis to allow preventive steps and slow clinical deterioration.
- 1 July 2025
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 15 (3)
Atypical Fibrodysplasia Ossificans Progressiva with G328E Variant and Digit Reduction Abnormalities
Case: Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant musculoskeletal disorder with progressive heterotopic ossification within soft connective tissues causing ankyloses and unique skeletal malformations of the big toes, which represent a birth hallmark for the disease. The classic variant is c.617G>A (p.Arg206His). We report 2 atypical FOP cases showing severe digit reduction, associated with a c.983G>A (p.Gly328Glu) variant in exon 8 of the ACVR1 gene. Conclusion: FOP should be ruled out in patients presenting with restricted movements of joints and spine and reduction of digits by clinical examination and molecular genetic analysis to allow preventive steps and slow clinical deterioration.
- Open Access
- 24 March 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 6 (3) , 361-372
Evaluation of safety and efficacy of multiple intravenous and intraosseous doses of foetal liver-derived mesenchymal stem cells in children with severe osteogenesis imperfecta
Aims: Current off-label bisphosphonate treatment for osteogenesis imperfecta (OI) does not induce healthy bone formation. Therefore, novel strategies to stimulate osteogenesis and reduce fractures are needed to meet the medical needs of these patients. Preclinical data and case studies show that multiple intravenous (IV) administrations of mesenchymal stem cells (MSCs) provide promising outcomes in the treatment of OI. In the Boost to Brittle Bones (BOOST2B) trial, we aim to assess the safety and tolerability of multiple IV and intraosseous (IO) administrations of foetal liver-derived MSCs in children aged one to five years diagnosed with severe OI.Methods: A total of 15 children will receive four doses of foetal MSCs IV (3 × 106 cells per kg of body weight) and IO (0.1 × 106 cells per kg of body weight per long bone) at four-month intervals. As a secondary endpoint, the therapeutic effect of the four MSC doses will be assessed based on the annual fracture rate, time to first fracture, bone mineral density, growth, clinical status of OI, and biochemical bone turnover in peripheral blood. Exploratory parameters include quality of life and donor cell engraftment.Conclusion: The BOOST2B trial has been approved by the regulatory agencies in India and is ongoing. It is the first clinical trial designed to evaluate IO administration of MSCs as a potential therapy for OI. Here, we describe the BOOST2B clinical trial protocol. The long-term data on safety and efficacy will be reported once completed.Cite this article: Bone Jt Open 2025;6(3):361–372.
- 24 March 2025
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 6 (3) , 361-372
Open AccessEvaluation of safety and efficacy of multiple intravenous and intraosseous doses of foetal liver-derived mesenchymal stem cells in children with severe osteogenesis imperfecta
Aims: Current off-label bisphosphonate treatment for osteogenesis imperfecta (OI) does not induce healthy bone formation. Therefore, novel strategies to stimulate osteogenesis and reduce fractures are needed to meet the medical needs of these patients. Preclinical data and case studies show that multiple intravenous (IV) administrations of mesenchymal stem cells (MSCs) provide promising outcomes in the treatment of OI. In the Boost to Brittle Bones (BOOST2B) trial, we aim to assess the safety and tolerability of multiple IV and intraosseous (IO) administrations of foetal liver-derived MSCs in children aged one to five years diagnosed with severe OI.Methods: A total of 15 children will receive four doses of foetal MSCs IV (3 × 106 cells per kg of body weight) and IO (0.1 × 106 cells per kg of body weight per long bone) at four-month intervals. As a secondary endpoint, the therapeutic effect of the four MSC doses will be assessed based on the annual fracture rate, time to first fracture, bone mineral density, growth, clinical status of OI, and biochemical bone turnover in peripheral blood. Exploratory parameters include quality of life and donor cell engraftment.Conclusion: The BOOST2B trial has been approved by the regulatory agencies in India and is ongoing. It is the first clinical trial designed to evaluate IO administration of MSCs as a potential therapy for OI. Here, we describe the BOOST2B clinical trial protocol. The long-term data on safety and efficacy will be reported once completed.Cite this article: Bone Jt Open 2025;6(3):361–372.
- 6 March 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (7) , e64023
COL1A1 and COL1A2 Gene Variants Causing Osteogenesis Imperfecta in a Major Referral Center of India
Heterozygous COL1A1 and COL1A2 gene variants are known to cause osteogenesis imperfecta (OI) in 90% of the patients in the Western and Japanese populations. Two previous Indian reports, a total of 49 patients, showed their proportion in the Indian population to be 44% and 71%. We studied a population of 210 children with a clinical diagnosis of OI and focused on the cohort of children with (likely) pathogenic COL1A1/COL1A2 variants. The prospective study describes the clinical, radiological, and genetic findings of 100 COL1A1/A2 variants. Phenotypic evaluation included the type of OI, fracture history, extraskeletal and skeletal features, pamidronate treatment, and its effect on bone density. Genotyping was assessed by clinical or targeted exome sequencing and validated by Sanger sequencing. One hundred patients, including affected siblings, out of 210 had COL1A1/A2 gene variants. No genetic cause was found in 25, and the remaining had causative variants in other OI‐associated genes. In the group of 100 children with (likely) pathogenic COL1A1/A2 variants, the proportions of phenotypes 1, 3, and 4 were 24%, 44%, and 32%, respectively. Consanguinity was 10%, which was less when compared to the other OI‐associated genes. The age of the first fracture was primarily at birth or before 6 months, particularly in severe types of OI such as Type III. Blue sclerae were observed in 84 patients, most commonly associated with OI Type I. Dentinogenesis imperfecta (DI) was present in 47 patients, typically seen in Types III and IV. Radiological features included Wormian bones in 58 patients, vertebral fractures in 46, and spine deformities in 16. Lower limb deformities were present in 90% of cases, with a higher prevalence in more severe forms of OI, while upper limb deformities were noted in 39%. Among the 22 patients receiving regular pamidronate therapy, there was a noticeable improvement in bone density, emphasizing the therapy's effectiveness, particularly in managing moderate to severe OI types. Genotypically, we report (likely) pathogenic 56 COL1A1 and 46 COL1A2 variants, including 21 novel variants. Of the 66 missense variants, 29 were in COL1A1 and 37 in COL1A2 genes. Of these, 60 were glycine substitutions (28 in COL1A1 and 32 in COL1A2) in the triple helix, the commonest being glycine to serine, associated with OI Type 3 in 28 individuals. The report highlights that 47.6% (100 out of 210 patients) of COL1A1 and COL1A2 gene variants were found in our cohort who underwent genetic analysis. This percentage is notably lower compared to other populations, where the percentage of identified COL1A1/2 variants has been reported to be higher.
- 6 March 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (7) , e64023
COL1A1 and COL1A2 Gene Variants Causing Osteogenesis Imperfecta in a Major Referral Center of India
Heterozygous COL1A1 and COL1A2 gene variants are known to cause osteogenesis imperfecta (OI) in 90% of the patients in the Western and Japanese populations. Two previous Indian reports, a total of 49 patients, showed their proportion in the Indian population to be 44% and 71%. We studied a population of 210 children with a clinical diagnosis of OI and focused on the cohort of children with (likely) pathogenic COL1A1/COL1A2 variants. The prospective study describes the clinical, radiological, and genetic findings of 100 COL1A1/A2 variants. Phenotypic evaluation included the type of OI, fracture history, extraskeletal and skeletal features, pamidronate treatment, and its effect on bone density. Genotyping was assessed by clinical or targeted exome sequencing and validated by Sanger sequencing. One hundred patients, including affected siblings, out of 210 had COL1A1/A2 gene variants. No genetic cause was found in 25, and the remaining had causative variants in other OI‐associated genes. In the group of 100 children with (likely) pathogenic COL1A1/A2 variants, the proportions of phenotypes 1, 3, and 4 were 24%, 44%, and 32%, respectively. Consanguinity was 10%, which was less when compared to the other OI‐associated genes. The age of the first fracture was primarily at birth or before 6 months, particularly in severe types of OI such as Type III. Blue sclerae were observed in 84 patients, most commonly associated with OI Type I. Dentinogenesis imperfecta (DI) was present in 47 patients, typically seen in Types III and IV. Radiological features included Wormian bones in 58 patients, vertebral fractures in 46, and spine deformities in 16. Lower limb deformities were present in 90% of cases, with a higher prevalence in more severe forms of OI, while upper limb deformities were noted in 39%. Among the 22 patients receiving regular pamidronate therapy, there was a noticeable improvement in bone density, emphasizing the therapy's effectiveness, particularly in managing moderate to severe OI types. Genotypically, we report (likely) pathogenic 56 COL1A1 and 46 COL1A2 variants, including 21 novel variants. Of the 66 missense variants, 29 were in COL1A1 and 37 in COL1A2 genes. Of these, 60 were glycine substitutions (28 in COL1A1 and 32 in COL1A2) in the triple helix, the commonest being glycine to serine, associated with OI Type 3 in 28 individuals. The report highlights that 47.6% (100 out of 210 patients) of COL1A1 and COL1A2 gene variants were found in our cohort who underwent genetic analysis. This percentage is notably lower compared to other populations, where the percentage of identified COL1A1/2 variants has been reported to be higher.
- 1 July 2024
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 14 (3)
Pamidronate Response in a Novel Biallelic CREB3L1 Gene Mutation–Associated Osteogenesis Imperfecta
Case: We report a 15-year-old adolescent boy being followed up for 6 years with osteogenesis imperfecta (OI). Genetic testing of this child revealed a novel missense variant c.925C>T p.Arg309Cys in the CREB3L1 gene. Treatment with regular pamidronate therapy showed increased bone mineral density and a reduced fracture rate. His lower limb rush rodding improved his mobility. His withdrawal from bisphosphonate therapy worsened his mobility status but started improving after he restarted treatment, suggesting a response to pamidronate therapy. Conclusion: We report a novel biallelic missense variant c.925C>T, p.Arg309Cys, in the CREB3L1 gene causing OI, which responded to bisphosphonate therapy and corrective surgery.
- 1 July 2024
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 14 (3)
Pamidronate Response in a Novel Biallelic CREB3L1 Gene Mutation–Associated Osteogenesis Imperfecta
Case: We report a 15-year-old adolescent boy being followed up for 6 years with osteogenesis imperfecta (OI). Genetic testing of this child revealed a novel missense variant c.925C>T p.Arg309Cys in the CREB3L1 gene. Treatment with regular pamidronate therapy showed increased bone mineral density and a reduced fracture rate. His lower limb rush rodding improved his mobility. His withdrawal from bisphosphonate therapy worsened his mobility status but started improving after he restarted treatment, suggesting a response to pamidronate therapy. Conclusion: We report a novel biallelic missense variant c.925C>T, p.Arg309Cys, in the CREB3L1 gene causing OI, which responded to bisphosphonate therapy and corrective surgery.
- Open Access
- 24 June 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 26, 324-333
Successful transport across continents of GMP-manufactured and cryopreserved culture-expanded human fetal liver-derived mesenchymal stem cells for use in a clinical trial
- 24 June 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 26, 324-333
Open AccessSuccessful transport across continents of GMP-manufactured and cryopreserved culture-expanded human fetal liver-derived mesenchymal stem cells for use in a clinical trial